您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Rozanolixizumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Rozanolixizumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1584645-37-3
包装与价格:
包装价格(元)
100 mg电议
500 mg电议

产品名称
UCB7665
产品介绍

产品描述

Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases.

体外活性

Rozanolixizumab binds to human FcRn and cynomolgus monkey FcRn with a similar affinity at both pH 6.0 (K d 23 pM and 25 pM, human and cynomolgus monkey, respectively) and pH 7.4 (34 pM and 53 pM, human and cynomolgus monkey, respectively. Rozanolixizumab is observed to inhibit the recycling (IC 50 0.41 nM) of human IgG by human FcRn-transfected MDCK cells in a dose-dependent manner. Recycling of IgG was also inhibits in cynomolgus monkey FcRn-transfected MDCK cells (IC 50 0.98nM)[1]. Rozanolixizumab causes an increase in intracellular IgG AF647[1].

体内活性

Intravenous (IV) rozanolixizumab dosing in cynomolgus monkeys demonstrated non-linear pharmacokinetics indicative of target-mediated drug disposition; single IV rozanolixizumab doses (30 mg/kg) in cynomolgus monkeys reduced plasma IgG concentration by 69% by Day 7 post-administration. Daily IV administration of rozanolixizumab (initial 30 mg/kg loading dose; 5 mg/kg daily thereafter) reduced plasma IgG concentrations in all cynomolgus monkeys, with low concentrations maintained throughout the treatment period (42 days)[1].

Cas No.

1584645-37-3

别名

UCB7665;Rozanolixizumab